Engage the immune system, improve outcomes in aCSCC

How are tumor cells evading the immune system in patients with aCSCC?

Explore the science behind tumor cell evasion

Review two critical immune responses and other challenges in immunotherapy

View in Browser

How can harnessing the potential of the immune system help fight aCSCC?

Dear [Dr] [Doe],

As the understanding of immunotherapy has progressed, we continue to learn more about the immune system and its role within the tumor microenvironment.

This includes the importance of the adaptive and innate immune responses to slow or potentially eliminate the growth of tumor cells. Leveraging this knowledge may help advance the treatment of patients with aCSCC.¹

The immune system targets cells through two critical defense mechanisms¹

The adaptive immune system is a highly specialized defense mechanism that can destroy tumor cells via a T-cell–mediated immune response.^1,2

The innate immune system is the body's first line of defense against pathogens. It is a rapid and broad-spectrum response, including NK cells in a critical role.¹

Learn about how tumor cells are evading these responses

aCSCC=advanced cutaneous squamous cell carcinoma (locally advanced and metastatic disease); NK=natural killer; PD-1=programmed cell-death protein 1; PD-L1=programmed death-ligand 1.

References: 1. Wang R, Lan C, Benlagha K, et al. The interaction of innate immune and adaptive immune system. MedComm (2020). 2024;5(10):e714. doi:10.1002/mco2.714 2. Chi H, Pepper M, Thomas PG. Principles and therapeutic applications of adaptive immunity. Cell. 2024;187(9):2052-2078. doi:10.1016/j.cell.2024.03.037

Sun Pharmaceutical Industries, Inc.
2 Independence Way
Princeton, NJ 08540

	Sun Pharmaceutical Industries, Inc. 2 Independence Way Princeton, NJ 08540

	© 2025 Sun Pharmaceutical Industries, Inc. All rights reserved. PM-US-NP-0168 10/25